MDL | MFCD00869254 |
---|---|
Molecular Weight | 287.30 |
Molecular Formula | C10H13N3O5S |
SMILES | O=S1(CC(C)N(/N=C/C2=CC=C([N+]([O-])=O)O2)CC1)=O |
Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi , has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase ( LDH ).
Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH). To differentiate if this effect is a result of a reduced LDH activity or a shift in pyruvate metabolism due to activation of PDH, the enzyme activity of LDH is determined after 4 h treatment with 50 µg/mL Nifurtimox. Compared to the untreated control, the LDH activity is significantly reduced for LA-N-1 (P=0.005), IMR-32 (P=0.009), LS (P=0.0035) and SK-N-SH (P=0.0065). Nifurtimox reduces cell viability and induces cell cycle arrest and apoptosis in neuroblastoma cells. To characterize the cytotoxic impacts of Nifurtimox on neuroblastoma, 4 cell lines are subjected to several experiments. Cell viability is reduced for all 4 neuroblastoma cell lines after 24 h incubation with 50 µg/mL to an average of 66%, 63%, 62% and 75% (LA-N-1, IMR-32 LS and SK-N-SH, respectively). The reduction is significant compared to the untreated control (P<0.01) and the vehicle control with DMSO (P<0.05) for all cell lines [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00486564 | University of Vermont|St. Louis University |
Neuroblastoma
|
November 2006 | Phase 1 |
NCT01685827 | Drugs for Neglected Diseases |
Human African Trypanosomiasis (HAT)|Sleeping Sickness
|
October 2012 | Phase 2|Phase 3 |
NCT00330148 | Epicentre|Médecins Sans Frontières, France|Embassy of France in Uganda|National Sleeping Sickness Control Program, Uganda |
Trypanosomiasis, African
|
March 2001 | Phase 3 |
NCT02606864 | Bayer |
Chagas Disease
|
December 2015 | Phase 1 |
NCT02369978 | Universidad Autónoma de Bucaramanga|Fundación Cardioinfantil Instituto de Cardiología|Instituto Nacional de Salud, Colombia|Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben |
Chagas Disease
|
August 2015 | Phase 2|Phase 3 |
NCT01927224 | Bayer |
Chagas Disease
|
November 2013 | Phase 1 |
NCT00601003 | Wake Forest University Health Sciences|Bayer |
Neuroblastoma|Medulloblastoma
|
February 2008 | Phase 2 |
NCT03981523 | University of Texas, El Paso|Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES)|Barcelona Institute for Global Health|Institute of Parasitology and Biomedicine Lopez Neyra|U.S. Food and Drug Administration (FDA)|Drugs for Neglected Diseases|Mundo Sano Foundation|National Institute of Allergy and Infectious Diseases (NIAID) |
Trypanosoma Cruzi Infection|Chagas Disease
|
December 18, 2019 | Phase 2 |
NCT03350295 | Bayer |
Chagas Disease
|
June 14, 2018 | Phase 1 |
NCT00489658 | Epicentre|Médecins Sans Frontières, France |
Trypanosomiasis, African
|
October 2002 | Phase 2|Phase 3 |
NCT03334838 | Bayer |
Chagas´ Disease
|
June 10, 2019 | Phase 1 |
NCT02625974 | Bayer |
Chagas Disease
|
January 27, 2016 | Phase 3 |
NCT00146627 | Drugs for Neglected Diseases|Medecins Sans Frontieres, Netherlands|PNLTHA-DRC;|PNLTHA-RoC|Epicentre|Swiss Tropical & Public Health Institute|World Health Organization |
Trypanosomiasis, African
|
Phase 3 | |
NCT05477953 | Bayer |
Chagas Disease
|
August 17, 2022 | |
NCT03708133 | Bayer |
Bioequivalence
|
December 5, 2018 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 150 mg/mL ( 522.10 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.4807 mL | 17.4034 mL | 34.8068 mL |
5 mM | 0.6961 mL | 3.4807 mL | 6.9614 mL |
10 mM | 0.3481 mL | 1.7403 mL | 3.4807 mL |